Wellmarker Bio Co., Ltd.

The Asan Foundation

Onconic Therapeutics Inc.

Seung Mi Kim

Eun Young Lee

Seung Woo Hong

Dae Hee Lee

Dong Hoon Jin

Seul Gee Lee

Eun Kyung Choi

Jeong Hee Kim

Jai Hee Moon

Jae Sik Shin

Seong Joon Park

Jung Shin Lee

Seung Hee Ha

Yong Sang Hong

Kyu Pyo Kim

Bong Choel Kim

Jae Lyun Lee

Ha Reum Lee

Eun Kyoung Choi

Ih Yeon Hwang

Soo A Jung

The present invention relates to a biomarker for predicting susceptibility to an MET inhibitor, and a use thereof, and more specifically, the present invention provides a method for predicting susceptibility to the MET inhibitor. According to the present invention, the present invention has an excellent effect of predicting susceptibility to the MET inhibitor for stomach cancer or lung cancer, and thus the present invention may be usefully employed for treating stomach cancer or lung cancer.

Combination method for treating cancer by targeting immunoglobulin superfamily member 1 (IGSF1) and mesenchymal-epithelial transition factor (MET)

The present disclosure relates to a new biomarker for predicting susceptibility to an EGFR-targeted agent and a use thereof, and more particularly, provides a biomarker for predicting susceptibility to an EGFR (Epidermal Growth Factor Receptor)-targeted agent, comprising a RON (Recepteur d'Origine Nantais) gene; a composition for predicting susceptibility to the EGFR-targeted agent, comprising an agent which measures a gene expression level of the biomarker; or an expression or activity level of a protein thereof; a composition for enhancing the susceptibility to the EGFR-targeted agent, comprising an inhibitor of the expression of the gene or the expression or activity of the protein of the gene as active ingredients; a kit for predicting the susceptibility to the EGFR-targeted agent, comprising the composition; and a method for predicting the susceptibility to the EGFR-targeted agent. According to the present disclosure, since an effect of predicting the susceptibility to the EGFR-targeted agent is excellent in a colon cancer, the present disclosure may be useful in the treatment of the colon cancer.

Biomarker for predicting sensitivity to EGFR-targeting agent, and use thereof

The present invention relates to a method for determining sensitivity to a simultaneous inhibitor against poly ADP ribose polymerase (PARP) and Tankyrase. According to the present invention, a colorectal treatment effect can be maximized by sorting patients having sensitivity to the simultaneous inhibitor against PARP and Tankyrase.

Method for determining sensitivity to simultaneous inhibitor against PARP and Tankyrase

Growing community of inventors

Seoul, South Korea

Seung Mi Kim